| 1 |
Skalicka H, Pudil R, Gregor P. Summary of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: Prepared by the Czech Society of Cardiology [J]. Cor Et Vasa, 2017.
|
| 2 |
中国临床肿瘤学会. 蒽环类药物心脏毒性防治指南(2013年版) [J]. 临床肿瘤学杂志, 2013, 18(10): 925-934.
|
| 3 |
Glass CK, Mitchell RN. Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity [J]. Cardiovasc Pathol, 2017, 30: 55-63.
|
| 4 |
Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines [J]. Ann Oncol, 2012, 23 Suppl 7: vii155- vii166.
|
| 5 |
陈炎, 陈亚蓓, 陶荣芳. 《ESMO 2012版临床实践指南解读——癌痛的管理,心血管毒性,化疗药物外渗的处理》解读 [J]. 中国现代医生, 2013, 51(20): 13-16.
|
| 6 |
Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography [J].J Am Soc Echocardiogr, 2013, 26(9): 1013-1032.
|
| 7 |
Negishi T, Negishi K. Echocardiographic evaluation of cardiac function after cancer chemotherapy [J]. J Echocardiogr, 2018, 16(1): 20-27.
|
| 8 |
Lópezfernández T, Martín GA, Santaballa BA, et al. Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations [J].Rev Esp Cardiol (Engl Ed), 2017, 70(6): 474-486.
|
| 9 |
Tarantini L, Massimo Gulizia M, Di Lenarda A, et al. ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary [J]. Eur Heart J Suppl, 2017, 19(Suppl D): D370-D379.
|
| 10 |
Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy [J]. J Am Coll Cardiol, 2010, 55(3): 213-220.
|
| 11 |
Tadic M, Cuspidi C, Hering D, et al. The influence of chemotherapy on the right ventricle: did we forget something? [J]. Clin Cardiol, 2017, 40(7): 437-443.
|
| 12 |
Boyd A, Stoodley P, Richards D, et al. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study [J]. PLoS One, 2017, 12(4): e0175544.
|
| 13 |
Toufan M, Pourafkari L, Ghahremani NL, et al. Two-dimensional strain echocardiography for detection of cardiotoxicity in breast cancer patients undergoing chemotherapy [J]. J Cardiovascul Thorac Res, 2016, 9(1): 29-34.
|
| 14 |
Song FY, Shi J, Guo Y, et al. Assessment of biventricular systolic strain derived from the two-dimensional and three-dimensional speckle tracking echocardiography in lymphoma patients after anthracycline therapy [J]. Int J Cardiovasc Imaging, 2017, 33(6): 857-868.
|
| 15 |
Zhang CJ, Pei XL, Song FY, et al. Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT [J]. Echocardiography, 2017, 34(11): 1593-1600.
|
| 16 |
Chang WT, Shih JY, Feng YH, et al. The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer [J]. Acta Cardiol Sin, 2016, 32(5): 550-559.
|
| 17 |
Płońska-Gościniak E, Różewicz M, Kasprzak J, et al. Tissue Doppler echocardiography detects subclinical left ventricular dysfunction in patients undergoing chemotherapy for colon cancer: insights from ONCOECHO multicentre study [J]. Kardiol Pol, 2017, 75(2): 150-156.
|
| 18 |
Santoro C, Arpino G, Esposito R, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility [J]. Eur Heart J Cardiovasc Imaging, 2017, 18(8): 930-936.
|
| 19 |
Kang Y, Xu X, Cheng L, et al. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy [J]. Eur J Heart Fail, 2014, 16(3): 300-308.
|
| 20 |
Tang Q, Jiang Y, Xu Y, et al. Speckle tracking echocardiography predicts early subclinical anthracycline cardiotoxicity in patients with breast cancer [J]. J Clin Ultrasound, 2017, 45(4): 222-230.
|
| 21 |
Venneri L, Zoppellaro G, Khattar RS. Cardio-oncology: the role of advanced echocardiography in cancer patients [J]. Expert Rev Cardiovasc Ther, 2018, 16(4): 249-258.
|
| 22 |
Nolan MT, Plana JC, Thavendiranathan P, et al. Cost-effectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity [J]. Int J Cardiol, 2016, 212: 336-345.
|
| 23 |
Luo R, Cui H, Huang D, et al. Early assessment of the left ventricular function by epirubicin-induced cardiotoxicity in postoperative breast cancer patients [J]. Echocardiography, 2017, 34(11): 1601-1609.
|
| 24 |
Paraskevaidis IA, Makavos G, Tsirigotis P, et al. Deformation Analysis of Myocardial Layers Detects Early Cardiac Dysfunction after Chemotherapy in Bone Marrow Transplantation Patients: A Continuous and Additive Cardiotoxicity Process [J]. J Am Soc Echocardiogr, 2017, 30(11): 1091-1102.
|
| 25 |
Shah KS, Yang EH, Maisel AS, et al. The Role of Biomarkers in Detection of Cardio-toxicity [J]. Curr Oncol Rep, 2017, 19(6): 42.
|
| 26 |
Narayan HK, Finkelman B, French B, et al. Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up [J]. Circulation, 2017, 135(15): 1397-1412.
|
| 27 |
Larsen CM, Mulvagh SL. Cardio-oncology: what you need to know now for clinical practice and echocardiography [J]. Echo Res Pract, 2017, 4(1): R33-R41.
|
| 28 |
Karaye KM, Sani MU. Factors associated with poor prognosis among patients admitted with heart failure in a Nigerian tertiary medical centre: a cross-sectional study [J]. BMC Cardiovasc Disord, 2008, 8: 16.
|
| 29 |
Haugaa KH, Edvardsen T. Global longitudinal strain: the best biomarker for predicting prognosis in heart failure? [J]. Eur J Heart Fail, 2016, 18(11): 1340-1341.
|
| 30 |
Virani SA, Dent S, Brezden-Masley C, et al. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy [J]. Can J Cardiol, 2016, 32(7): 831-841.
|